Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-8722
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML ; volume:14 ; number:1 ; day:23 ; month:2 ; year:2021 ; pages:1-2 ; date:12.2021
Journal of hematology & oncology ; 14, Heft 1 (23.2.2021), 1-2, 12.2021
- Urheber
-
Yilmaz, Musa
Alfayez, Mansour
DiNardo, Courtney D.
Borthakur, Gautam
Kadia, Tapan M.
Konopleva, Marina Y.
Loghavi, Sanam
Kanagal-Shamanna, Rashmi
Patel, Keyur P.
Jabbour, Elias J.
Garcia‑Manero, Guillermo
Pemmaraju, Naveen
Pierce, Sherry A.
Ghayas, Issa
Short, Nicholas J.
Montalban-Bravo, Guillermo
Takahashi, Koichi
Assi, Rita
Alotaibi, Ahmad S.
Ohanian, Maro
Andreeff, Michael
Cortes, Jorge E.
Kantarjian, Hagop M.
Ravandi, Farhad
Daver, Naval G.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13045-020-01023-9
- URN
-
urn:nbn:de:101:1-2021041013044504747275
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:53 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Yilmaz, Musa
- Alfayez, Mansour
- DiNardo, Courtney D.
- Borthakur, Gautam
- Kadia, Tapan M.
- Konopleva, Marina Y.
- Loghavi, Sanam
- Kanagal-Shamanna, Rashmi
- Patel, Keyur P.
- Jabbour, Elias J.
- Garcia‑Manero, Guillermo
- Pemmaraju, Naveen
- Pierce, Sherry A.
- Ghayas, Issa
- Short, Nicholas J.
- Montalban-Bravo, Guillermo
- Takahashi, Koichi
- Assi, Rita
- Alotaibi, Ahmad S.
- Ohanian, Maro
- Andreeff, Michael
- Cortes, Jorge E.
- Kantarjian, Hagop M.
- Ravandi, Farhad
- Daver, Naval G.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
Dendritic cell dysfunctions in AML patients with FLT3 ITD mutations
Dendritic Cell dysfunctions in AML patients with FLT3 ITD mutations
Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitors
Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD–positive AML
FLT3-ITD regulated miRs in AML
Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurina
CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML
Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia
FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML
BCL-2 inhibition synergizes with dual targeting of FLT3 and AXL in FLT3 wildtype AML via downregulation of MCL-1
Effekte von FLT3-ITD Inhibitoren auf Chemotherapie resistente AML Zelllinien
Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
Dendritic cell dysfunctions in AML patients with FLT3 ITD mutations
Dendritic Cell dysfunctions in AML patients with FLT3 ITD mutations
Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitors
Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD–positive AML
FLT3-ITD regulated miRs in AML
Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurina
CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML
Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia
FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML
BCL-2 inhibition synergizes with dual targeting of FLT3 and AXL in FLT3 wildtype AML via downregulation of MCL-1
Effekte von FLT3-ITD Inhibitoren auf Chemotherapie resistente AML Zelllinien
Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
Dendritic cell dysfunctions in AML patients with FLT3 ITD mutations
Dendritic Cell dysfunctions in AML patients with FLT3 ITD mutations
Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitors
Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD–positive AML
FLT3-ITD regulated miRs in AML
Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurina
CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML
Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia
FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML
BCL-2 inhibition synergizes with dual targeting of FLT3 and AXL in FLT3 wildtype AML via downregulation of MCL-1